Natasha B. Leighl

43.9k total citations · 10 hit papers
537 papers, 18.7k citations indexed

About

Natasha B. Leighl is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Natasha B. Leighl has authored 537 papers receiving a total of 18.7k indexed citations (citations by other indexed papers that have themselves been cited), including 373 papers in Pulmonary and Respiratory Medicine, 321 papers in Oncology and 117 papers in Cancer Research. Recurrent topics in Natasha B. Leighl's work include Lung Cancer Treatments and Mutations (325 papers), Lung Cancer Research Studies (131 papers) and Lung Cancer Diagnosis and Treatment (124 papers). Natasha B. Leighl is often cited by papers focused on Lung Cancer Treatments and Mutations (325 papers), Lung Cancer Research Studies (131 papers) and Lung Cancer Diagnosis and Treatment (124 papers). Natasha B. Leighl collaborates with scholars based in Canada, United States and Spain. Natasha B. Leighl's co-authors include Frances A. Shepherd, Ronald Feld, Ming‐Sound Tsao, Monika K. Krzyzanowska, Gary Rodin, Camilla Zimmermann, Peter Ellis, Nadia Swami, Breffni Hannon and Ian F. Tannock and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Natasha B. Leighl

510 papers receiving 18.4k citations

Hit Papers

Early palliative care for... 2009 2026 2014 2020 2014 2009 2015 2018 2017 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
    2014 1.2k citations Natasha B. Leighl et al. profile →
  2. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
    2009 1.2k citations Natasha B. Leighl et al. Journal of Clinical Oncology profile →
  3. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
    2015 589 citations Natasha B. Leighl, James L. Wade et al. Journal of Clinical Oncology profile →
  4. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
    2018 511 citations Natasha B. Leighl, Suresh S. Ramalingam et al. Journal of Clinical Oncology profile →
  5. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2017 471 citations Peter Ellis, Natasha B. Leighl et al. Journal of Clinical Oncology profile →
  6. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
    2017 430 citations Marcello Tiseo, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →
  7. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
    2019 408 citations Natasha B. Leighl, Ray D. Page et al. Clinical Cancer Research profile →
  8. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
    2018 342 citations Natasha B. Leighl, Suresh S. Ramalingam et al. Journal of Clinical Oncology profile →
  9. Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials
    2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →
  10. Perceptions of palliative care among patients with advanced cancer and their caregivers
    2016 259 citations Natasha B. Leighl et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Natasha B. Leighl Canada 63 10.5k 10.2k 3.2k 3.2k 3.0k 537 18.7k
Dae Seog Heo South Korea 67 10.1k 1.0× 6.9k 0.7× 2.1k 0.7× 3.7k 1.2× 1.7k 0.6× 472 17.9k
Neal J. Meropol United States 61 13.1k 1.2× 5.2k 0.5× 3.5k 1.1× 3.1k 1.0× 1.6k 0.5× 307 19.4k
Arti Hurria United States 67 9.6k 0.9× 4.9k 0.5× 2.4k 0.7× 976 0.3× 3.4k 1.1× 322 20.3k
Nadia Howlader United States 28 8.5k 0.8× 4.5k 0.4× 3.2k 1.0× 3.1k 1.0× 1.5k 0.5× 52 17.4k
Lynn A. G. Ries United States 56 13.0k 1.2× 6.6k 0.6× 3.6k 1.1× 4.1k 1.3× 3.1k 1.0× 81 26.7k
Richard L. Schilsky United States 75 13.8k 1.3× 6.0k 0.6× 5.3k 1.7× 4.8k 1.5× 1.8k 0.6× 382 23.2k
Phyllis A. Wingo United States 52 9.4k 0.9× 4.9k 0.5× 2.7k 0.8× 4.2k 1.3× 1.7k 0.6× 105 20.8k
Bruce J. Trock United States 68 4.8k 0.5× 9.7k 0.9× 2.1k 0.7× 3.6k 1.1× 878 0.3× 337 17.9k
Betsy Kohler United States 30 6.2k 0.6× 2.9k 0.3× 2.0k 0.6× 2.6k 0.8× 1.4k 0.5× 61 13.9k
Gregory R. Pond Canada 65 5.7k 0.5× 5.6k 0.6× 1.9k 0.6× 2.6k 0.8× 1.2k 0.4× 575 15.8k

Countries citing papers authored by Natasha B. Leighl

Since Specialization
Citations

This map shows the geographic impact of Natasha B. Leighl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natasha B. Leighl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natasha B. Leighl more than expected).

Fields of papers citing papers by Natasha B. Leighl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natasha B. Leighl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natasha B. Leighl. The network helps show where Natasha B. Leighl may publish in the future.

Co-authorship network of co-authors of Natasha B. Leighl

This figure shows the co-authorship network connecting the top 25 collaborators of Natasha B. Leighl. A scholar is included among the top collaborators of Natasha B. Leighl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natasha B. Leighl. Natasha B. Leighl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pillay, Jennifer, Scott Klarenbach, Donna L. Reynolds, et al.. (2024). Screening for lung cancer with computed tomography: protocol for systematic reviews for the Canadian Task Force on Preventive Health Care. Systematic Reviews. 13(1). 88–88. 4 indexed citations
3.
Erickson, Anders W., Manmeet S. Ahluwalia, Minesh P. Mehta, et al.. (2023). Prophylactic cranial irradiation in small cell lung cancer patients in the era of magnetic resonance imaging: A systematic review and meta-analysis.. Journal of Clinical Oncology. 41(16_suppl). e20636–e20636. 1 indexed citations
4.
Parmar, Ambica, et al.. (2022). Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. 173. 103660–103660. 9 indexed citations
5.
Ionescu, Diana N., Tracy Stockley, Shantanu Banerji, et al.. (2022). Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. Current Oncology. 29(7). 4981–4997. 20 indexed citations
6.
Page, Ray D., Leylah Drusbosky, Victoria M. Raymond, et al.. (2021). Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 72–81. 31 indexed citations
7.
Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973. 38 indexed citations
8.
Li, Janice J.N., Mike Sung, Lisa W. Le, et al.. (2020). Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. Lung Cancer. 150. 159–163. 31 indexed citations
9.
Huber, Rudolf M., Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, et al.. (2019). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology. 15(3). 404–415. 101 indexed citations
10.
Leighl, Natasha B., Ray D. Page, Victoria M. Raymond, et al.. (2019). Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Clinical Cancer Research. 25(15). 4691–4700. 408 indexed citations breakdown →
11.
Ezeife, Doreen A., François Dionne, Aline Fusco Fares, et al.. (2019). Value assessment of oncology drugs using a weighted criterion‐based approach. Cancer. 126(7). 1530–1540. 10 indexed citations
12.
Raman, Srinivas, Jean‐Pierre Bissonnette, Andrew Warner, et al.. (2018). Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non–small-cell Lung Cancer (NCT02788461). Clinical Lung Cancer. 19(5). e699–e703. 13 indexed citations
13.
Grosso, Federica, Nicola Steele, Silvia Novello, et al.. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. 35(31). 3591–3600. 77 indexed citations
14.
Tomasini, Pascale, et al.. (2016). Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. The Oncologist. 21(12). 1450–1460. 96 indexed citations
15.
16.
Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →
17.
Partridge, Ann H., Davinia Seah, Natasha B. Leighl, et al.. (2014). Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now. Journal of Clinical Oncology. 32(29). 3330–3336. 69 indexed citations
18.
Sacher, Adrian G., Lisa W. Le, & Natasha B. Leighl. (2014). Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping. Journal of Clinical Oncology. 32(14). 1407–1411. 33 indexed citations
19.
Coate, Linda & Natasha B. Leighl. (2011). How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology. 12(1). 1–11. 10 indexed citations
20.
Lwin, Zarnie & Natasha B. Leighl. (2009). Economic evaluation of docetaxel for breast cancer. Expert Opinion on Pharmacotherapy. 10(2). 283–290. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dae Seog Heo Breakdown of academic impact, for papers by Neal J. Meropol Breakdown of academic impact, for papers by Arti Hurria Breakdown of academic impact, for papers by Nadia Howlader Breakdown of academic impact, for papers by Lynn A. G. Ries Breakdown of academic impact, for papers by Richard L. Schilsky Breakdown of academic impact, for papers by Phyllis A. Wingo Breakdown of academic impact, for papers by Bruce J. Trock Breakdown of academic impact, for papers by Betsy Kohler Breakdown of academic impact, for papers by Gregory R. Pond
Rankless by CCL
2026